Impact on healthcare resource usage and costs among Medicaid-insured schizophrenia patients after initiation of treatment with long-acting injectable antipsychotics

Journal of Medical Economics

Volumn 16, Issue 4, 2013, Pages 522-528

  Bera, Rimal ^a   Offord, Steve ^b   Zubek, Donna ^b   Lau, Gina ^b   Lin, Jay ^c   Baker, Ross A ^b   Karson, Craig ^d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b OTSUKA PHARMACEUTICAL DEVELOPMENT AND COMMERCIALIZATION INC   (United States)

^c Novosys Health   (United States)

^d CNK Consultants   (United States)

Author keywords

Healthcare costs; Healthcare resource usage; Long acting injectable antipsychotics; Schizophrenia

Indexed keywords

ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTIPYRETIC AGENT; ANXIOLYTIC AGENT; ARIPIPRAZOLE; CLOZAPINE; FLUPHENAZINE; FLUPHENAZINE DECANOATE; HALOPERIDOL; HALOPERIDOL DECANOATE; NEUROLEPTIC AGENT; OLANZAPINE; PALIPERIDONE; PERPHENAZINE; QUETIAPINE; RISPERIDONE;

ADOLESCENT; ADULT; AGED; AMBULATORY CARE; ARTICLE; CHARLSON COMORBIDITY INDEX; CHRONIC LUNG DISEASE; DIABETES MELLITUS; FEMALE; FOLLOW UP; HEALTH CARE COST; HEALTH CARE DELIVERY; HEALTH CARE UTILIZATION; HEALTH IMPACT ASSESSMENT; HOSPITALIZATION; HUMAN; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MEDICAID; MENTAL PATIENT; OUTCOME ASSESSMENT; PRESCRIPTION; RACE; RETROSPECTIVE STUDY; SCHIZOPHRENIA; TREATMENT DURATION;

ADOLESCENT; ADULT; AGED; ANTIPSYCHOTIC AGENTS; COMORBIDITY; DELAYED-ACTION PREPARATIONS; FEMALE; HEALTH EXPENDITURES; HEALTH SERVICES; HUMANS; INJECTIONS; INSURANCE CLAIM REVIEW; MALE; MEDICAID; MIDDLE AGED; RETROSPECTIVE STUDIES; SCHIZOPHRENIA; UNITED STATES; YOUNG ADULT;

EID: 84875718784     PISSN: 13696998     EISSN: 1941837X     Source Type: Journal    
DOI: 10.3111/13696998.2013.771641     Document Type: Article

References (17)

1. New York State. Office of Mental Health. 2005-2009 Statewide Comprehensive Plan for Mental Health Service Services. Chapter 4: basic and clinical research. Albany, New York: New York Sate Office of Mental Health. 2012. http://www.omh.ny.gov/omhweb/statewideplan/2005/chapter4.htm. Accessed August 27, 2012
2. West JC, Marcus SC, Wilk J, et al. Use of depot antipsychotic medications for medication nonadherence in schizophrenia. Schizophr Bull 2008; 34:995-1001
3. Lacro JP, Dunn LB, Dolder CR, et al. Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. J Clin Psychiatry 2002;63:892-909
4. Lambert T, Olivares JM, Peuskens J, et al. Effectiveness of injectable risperidone long-acting therapy for schizophrenia: data from the US, Spain, Australia, and Belgium. Ann Gen Psychiatry 2011;10:10
5. Olfson M, Marcus SC, Ascher-Svanum H. Treatment of schizophrenia with long-acting fluphenazine, haloperidol, or risperidone. Schizophr Bull 2007; 33:1379-87
6. Fuller M, Shermock K, Russo P, et al. Hospitalisation and resource utilisation in patients with schizophrenia following initiation of risperidone longacting therapy in the Veterans Affairs Healthcare System. J Med Econ 2009;12:317-24
7. Niaz OS, Haddad PM. Thirty-five months experience of risperidone longacting injection in a UK psychiatric service including a mirror-image analysis of in-patient care. Acta Psychiatr Scand 2007;116:36-46
8. Peng X, Ascher-Svanum H, Faries D, et al. Decline in hospitalization risk and health care cost after initiation of depot antipsychotics in the treatment of schizophrenia. Clinicoecon Outcomes Res 2011;3:9-14
9. Young CL, Taylor DM. Health resource utilization associated with switching to risperidone long-acting injection. Acta Psychiatr Scand 2006;114:14-20
10. Taylor D, Fischetti C, Sparshatt A, et al. Risperidone long-acting injection: a 6-year mirror-image study of healthcare resource use. Acta Psychiatr Scand 2009;120:97-101
11. Noordsy DL, Phillips GA, Ball DE, et al. Antipsychotic adherence, switching, and health care service utilization among Medicaid recipients with schizophrenia. Patient Prefer Adherence 2010;4:263-71
12. US Department of Health and Human Services. Code of Federal Regulations. Human Subjects Research (45 CFR 46), Washington D.C.: US Department of Health and Human Services. 2009
13. Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373-83
14. Brown, JD, Barrett A, Ireys H, et al. Evidence-based practices for Medicaid Beneficiaries with schizophrenia and bipolar disorder. Washington D.C.: U.S. Department of Health and Human Services, 2012. http://aspe.hhs.gov/daltcp/ reports/2012/ebpsbd.shtml. Accessed August 28, 2012
15. Brissos S, Dias VV, Balanza-Martinez V, et al. Symptomatic remission in schizophrenia patients: relationship with social functioning, quality of life, and neurocognitive performance. Schizophr Res 2011;129:133-6
16. Cuyun Carter GB, Milton DR, Ascher-Svanum H, et al. Sustained favorable long-term outcome in the treatment of schizophrenia: a 3-year prospective observational study. BMC Psychiatry 2011;11:143
17. Macfadden W, DeSouza C, Crivera C, et al. Assessment of effectiveness measures in patients with schizophrenia initiated on risperidone long-acting therapy: the SOURCE study results. BMC Psychiatry 2011;11:167